My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 9 498 / DOI: 10.3332/ecancer.2015.498

Policy

PACE Continuous Innovation Indicators—a novel tool to measure progress in cancer treatments

Concerns about rising health care costs and the often incremental nature of improvements in health outcomes continue to fuel intense debates about ‘progress’ and ‘value’ in cancer research. In times of tightening fiscal constraints, it is increasingly important for patients and their representatives to define what constitutes ’value’ to them. It is clear that diverse stakeholders have different priorities. Harmonisation of values may be neither possible nor desirable. Stakeholders lack tools to visualise or otherwise express these differences and to track progress in cancer treatments based on variable sets of values.

The Patient Access to Cancer care Excellence (PACE) Continuous Innovation Indicators are novel, scientifically rigorous progress trackers that employ a three-step process to quantify progress in cancer treatments: 1) mine the literature to determine the strength of the evidence supporting each treatment; 2) allow users to weight the analysis according to their priorities and values; and 3) calculate Evidence Scores (E-Scores), a novel measure to track progress, based on the strength of the evidence weighted by the assigned value.

We herein introduce a novel, flexible value model, show how the values from the model can be used to weight the evidence from the scientific literature to obtain E-Scores, and illustrate how assigning different values to new treatments influences the E-Scores.

The Indicators allow users to learn how differing values lead to differing assessments of progress in cancer research and to check whether current incentives for innovation are aligned with their value model. By comparing E-Scores generated by this tool, users are able to visualise the relative pace of innovation across areas of cancer research and how stepwise innovation can contribute to substantial progress against cancer over time. Learning from experience and mapping current unmet needs will help to support a broad audience of stakeholders in their efforts to accelerate and maximise progress against cancer.

Keywords: cancer, innovation, value, indicators, progress

Loading Article Metrics ... Please wait

Author interviews

Gordon McVie

European Institute of Oncology, Milan, Italy and Founding Editor of ecancer.org

Related videos

Related articles

Review: Bringing a humanistic approach to cancer clinical trials

Abstract | Full Article | PDF Published: 18 May 2017 / DOI: 10.3332/ecancer.2017.738

Case Report: Volumetric arc therapy for total scalp irradiation: case report for a recurrent basal cell carcinoma of the scalp

Abstract | Full Article | PDF Published: 11 May 2017 / DOI: 10.3332/ecancer.2017.737

Review: Nursing diagnoses in adult/elderly patients undergoing outpatient antineoplastic chemotherapy: a review

Abstract | Full Article | PDF | Portuguese Published: 03 May 2017 / DOI: 10.3332/ecancer.2017.736

Image Report: Brachytherapy and anterior segment imaging in iris melanoma

Abstract | Full Article | PDF Published: 18 Apr 2017 / DOI: 10.3332/ecancer.2017.734

Case Report: Unusual tumour ablations: report of difficult and interesting cases

Abstract | Full Article | PDF Published: 18 Apr 2017 / DOI: 10.3332/ecancer.2017.733



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence